Login to Your Account



BIOTECHS NOT READY FOR PRIME TIME

Barely on the radar, biotech M&As in China are growing

By Shannon Ellis
Staff Writer

Tuesday, April 8, 2014
SHANGHAI – Chinese biotech companies are only a small part of the M&A pie in the drug sector here. Although big pharma deals continue to take more than half of all M&A deals in life sciences with 20 percent growth over last year, innovative biotech hardly registers on the scale.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription